Table 1

Characteristics of n-butyl cyanoacrylate studies

StudiesNo of patientsMales (n (%))Study periodGrades I, II (%)Agent
Wilams et al2285 (62.5)NANANBCA
Jafar et al23209 (45)1989–1990NANBCA
Wikholm24*134NA1987–1992NANBCA (all), PVA (1)
DeMeritt et al2530NA1992–199310NBCA
Dubrun et al2654NA1994–1995NANBCA
Deruty et al2752NA1989–199555NBCA
Liu et al28103NA1987–199824NBCA
Hartmann et al29233109 (46.8)1991–199824NBCA
n-BCA trial305233 (63.5)1996–199934NBCA
FDA trial315427 (50)NA51NBCA
Yu et al322715 (55.6)1995–199751NBCA
Klurfan et al33155110 (71)1994–2004NANBCA
Pongpech et al34176NA1995–200538NBCA (all), coil (2)
Bhattacharya et al35127NA1998–2005NANBCA
Li et al36469296 (63.1)1988–200556NBCA
Raymond et al37227103 (45.4)1994–2004NANBCA
Ledezm et al38168103 (61.3)1993–200438NBCA
Cronqvist et al392115 (71.4)1999–200338NBCA (all), EVOH (5 embolized)
Velat et al406035 (58.3)2002–200688NBCA
Loh et al416331 (49.2)2001–200350NBCA
Sahlein et al42§13064 (49.2)1997–200633NBCA (all), PVA (15%)
  • *One case embolized with PVA.

  • †Coil was used in two cases.

  • ‡EVOH was used in five sessions.

  • §PVA was used as complementary in 15% of patients.

  • EVOH, ethylene-vinyl alcohol co-polymer; NA, not available; NBCA, n-butyl cyanoacrylate; PVA, polyvinyl alcohol.